A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants

The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.

Inclusion Criteria:

• Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology
• Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy)
• Available tumor samples for centralized testing
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
• Measurable disease

Exclusion Criteria:

• Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma
• Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy
• Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy)

Other protocol-defined inclusion/exclusion criteria apply